Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHaemonetics Corporation

Haemonetics Corporation

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
118.21 USD -1.72 ( 1.43%)
Last update at 2026-11-09T21:05:00Z
VOLUME
999282
Market Cap
4831.79M
P/E
51.30

Momentum Score

…

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
117.48
Low
122.97
High
52 Week Price Range
47.32
Low
109.57
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Haemonetics Corporation makes blood-management systems, disposables and software used by hospitals, blood centers and manufacturers to collect, process and transfuse blood products. Long-term growth drivers include recurring consumable revenue from disposables, aging populations and surgical demand, international expansion and product innovation in automation and data-enabled solutions. The company may appeal to investors for its installed base supporting predictable consumable sales and a business model that could support margin improvement over time.

Key investment risks include regulatory and reimbursement pressures, competition from larger medical-device companies, sensitivity to elective surgery and donation volumes, and execution or supply-chain challenges that could constrain growth and margins.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
119.93
Dividend Yield
-
Revenue TTM
1352.01M
Revenue Per Share
29.08
Gross Profit TTM
802.16M
Debt / Equity
1.54
ROE
11.20%
Net Debt
979.14M
ROCE
7.42%
Diluted EPS TTM
2.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax 128.03M 212.07M 151.87M 141.40M 63.63M
Net income 97.31M 167.68M 117.56M 115.40M 43.38M
Selling general administrative 442.42M 414.35M 413.72M 376.68M 339.56M
Selling and marketing expenses - 7.70M 7.10M - -
Gross profit 743.59M 778.55M 711.91M 615.10M 505.50M
Reconciled depreciation 111.72M 115.59M 97.22M 93.31M 97.75M
Ebit 156.73M 247.10M 206.84M 156.03M 80.75M
Ebitda 312.45M 355.99M 295.45M 249.34M 169.47M
Depreciation and amortization 155.72M 108.89M 88.61M 93.31M 88.72M
Non operating income net other - - - -14.63M -17.12M
Operating income 241.40M 221.82M 164.88M 156.03M 80.75M
Other operating expenses 1092.63M 1139.01M 1144.17M 459.06M 921.47M
Interest expense 28.70M 9.75M 13.02M 14.63M 17.12M
Tax provision 30.72M 44.39M 34.31M 26.00M 20.25M
Interest income - 9.75M 13.02M 14.63M 17.12M
Net interest income -28.70M -9.75M -13.02M -14.63M -17.12M
Non recurring - - - - 0.58M
Income tax expense 30.72M 44.39M 34.31M 26.00M 20.25M
Total revenue 1334.03M 1360.82M 1309.06M 1168.66M 993.20M
Total operating expenses 502.19M 556.73M 547.03M 459.06M 433.78M
Cost of revenue 590.44M 582.28M 597.14M 553.56M 487.69M
Total other income expense net -113.37M -9.75M -13.02M -14.63M -17.12M
Net income from continuing ops 97.31M 167.68M 117.56M 115.40M 43.38M
Net income applicable to common shares - 167.68M 117.56M 115.40M 43.38M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 2395.93M 2450.95M 2195.59M 1934.83M 1859.73M
Intangible assets 447.65M 455.74M 406.12M 275.77M 310.26M
Other current assets 66.21M 60.41M 66.34M 46.73M 44.13M
Total liab 1599.61M 1630.11M 1235.63M 1116.83M 1110.31M
Total stockholder equity 796.32M 820.84M 959.96M 818.00M 749.42M
Deferred long term liab - - - 36.20M 28.73M
Other current liab 184.22M 164.21M 185.55M 145.89M 137.92M
Common stock 0.45M 0.48M 0.51M 0.50M 0.51M
Capital stock 0.45M 0.48M 0.51M 0.50M 0.51M
Retained earnings 279.34M 352.17M 360.46M 253.17M 202.39M
Other liab - - - - 108.60M
Good will 656.37M 604.27M 565.08M 466.23M 467.29M
Other assets - 0.00M 0.00M 58.80M 67.67M
Cash 245.44M 306.76M 178.80M 284.47M 259.50M
Cash and equivalents - 306.76M 178.80M 284.47M 259.50M
Total current liabilities 282.60M 578.11M 300.38M 251.82M 442.27M
Current deferred revenue 42.31M 43.35M 31.24M 30.21M 31.83M
Net debt 979.14M 918.02M 628.99M 481.42M 514.09M
Short term debt 5.01M 303.56M 10.23M 11.78M 214.15M
Short long term debt 5.01M 303.56M 10.23M 11.78M 214.15M
Short long term debt total 1224.58M 1224.79M 807.79M 765.89M 773.59M
Other stockholder equity 554.14M 523.26M 634.63M 594.71M 572.48M
Property plant equipment - 331.54M 366.63M 310.88M 258.48M
Total current assets 834.88M 934.98M 768.90M 769.72M 756.03M
Net tangible assets - - - 76.00M -28.12M
Short term investments - - 1.67M - -
Net receivables 216.85M 202.66M 206.56M 179.14M 159.38M
Long term debt 1219.57M 921.23M 797.56M 754.10M 559.44M
Inventory 306.37M 365.14M 317.20M 259.38M 293.03M
Accounts payable 51.06M 67.00M 73.36M 63.93M 58.37M
Accumulated other comprehensive income -37.61M -55.08M -35.63M -30.38M -25.95M
Common stock total equity - - - 0.50M 0.51M
Retained earnings total equity - - - 253.17M 202.39M
Non currrent assets other 141.74M 164.11M 81.12M 106.97M 63.20M
Non current assets total 1561.05M 1515.97M 1426.69M 1165.10M 1103.70M
Capital lease obligations - - - - 7.20M
Long term debt total - 921.23M 797.56M 754.10M 559.44M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments -36.07M -161.90M -322.39M -143.79M -86.34M
Change to liabilities - - - 39.82M 7.64M
Total cashflows from investing activities -179.55M -161.90M -322.39M -143.79M -86.34M
Net borrowings -6.25M 447.31M 37.75M 269.26M -17.50M
Total cash from financing activities -178.46M 108.82M 38.16M -100.36M -15.75M
Change to operating activities - - - - -4.51M
Net income 97.31M 167.68M 117.56M 115.40M 43.38M
Change in cash -61.32M 127.96M -105.67M 24.97M 67.19M
Begin period cash flow 306.76M 178.80M 284.47M 259.50M 192.31M
End period cash flow 245.44M 306.76M 178.80M 284.47M 259.50M
Total cash from operating activities 293.22M 181.72M 181.75M 273.06M 172.26M
Depreciation 111.72M 115.59M 97.22M 93.31M 97.75M
Other cashflows from investing activities -87.96M -15.00M -13.74M -0.39M 10.16M
Change to inventory 47.36M -64.70M -60.06M 30.75M 24.31M
Change to account receivables -14.88M 6.96M -24.19M -24.42M -34.97M
Sale purchase of stock -175.00M -225.00M -5.88M -75.00M 6.55M
Other cashflows from financing activities -5.10M -113.49M -6.81M -15.74M 1.75M
Change to netincome - - - 36.21M 46.32M
Capital expenditures 32.78M 39.28M 66.30M 110.19M 96.51M
Change receivables - - - -24.42M -34.97M
Cash flows other operating - - - -19.98M -22.62M
Cash and cash equivalents changes - - - 28.91M 70.17M
Change in working capital -23.65M -101.96M -74.70M 25.50M -15.18M
Stock based compensation 33.83M 29.64M 28.33M 25.58M 24.36M
Other non cash items 74.74M -24.00M 24.39M 8.48M 16.95M
Free cash flow 260.44M 142.45M 115.45M 162.87M 75.75M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HAE
Haemonetics Corporation		 -1.72
1.43%		 118.21 51.30 20.20 3.57 5.78 4.28 21.40
ABT
Abbott Laboratories		 -0.02
0.02%		 110.51 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 1.00
0.98%		 102.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -
-%		 325.73 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.56
1.12%		 50.41 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Haemonetics Corporation

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

125 Summer Street, Boston, MA, United States, 02110

781 848 7100

https://www.haemonetics.com

3009

Name Title Year Born
Mr. Christopher A. Simon CEO, Pres & Director 1964
Mr. Josep Lluis Llorens Exec. VP of Global Manufacturing & Supply Chain 1963
Mr. Stewart W. Strong Pres of Global Hospital 1967
Mr. James C. D'Arecca CPA CFO, Exec. VP & Financial Officer 1971
Ms. Farris Maryanne Maunsell VP, Chief Accounting Officer & Principal Accounting Officer 1975
Ms. Anila Lingamneni Exec. VP & CTO 1968
Ms. Olga Guyette Director of Investor Relations NA
Carla Burigatto VP of Communications NA
Mr. Francis Tan Sr. VP of Corp. Devel. & Planning NA
Ms. Laurie A. Miller Sr. VP & Chief HR Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…